HealthEquity cleared its June 2 earnings hurdle with a modest gain, but the post-print session has brought sellers back into the stock — and the options market, which was screaming bullish just days ago, has quietly stayed there.
The earnings reaction was muted but positive. The stock rose roughly 1.7% on May 28 after the print, a restrained response given how aggressively bullish options traders had been positioned heading in. The put/call ratio had collapsed to 0.32 before the release — near its 52-week low — a reading that implied genuine conviction rather than casual optimism. That conviction has carried over: the PCR remains at 0.32, still nearly two standard deviations below its 20-day average of 0.61. Investors are not rushing to buy protection, even after a 2.5% pullback on June 2 brought the stock to $88.34.
Short interest adds a layer of complexity to the post-earnings picture. Bears added slightly on Tuesday, with short interest ticking up 0.4% in a single session to 5.5% of the float — but the monthly direction is actually more bearish than that daily number implies. SI has climbed roughly 11% over the past month, reaching 4.75 million shares, even as it dipped 4.2% on the week. The lending market remains extraordinarily relaxed: availability is running at 1,272% — meaning roughly twelve shares are available to borrow for every one already shorted. Cost to borrow has edged up 35% over the past month but is still only 0.42% annualised. There is no squeeze dynamic building here.
The Street is broadly aligned on the bull side, though its enthusiasm has a ceiling. RBC Capital reiterated its Outperform rating with a $108 target just this week, while Citizens nudged its target up to $111 from $110 on June 1. Those moves follow a busy May in which Barrington Research and BMO Capital both maintained positive ratings. The consensus target is $114.63, implying around 30% upside to Tuesday's close. The bull case centers on HealthEquity's dominant position in the HSA market and improving EBITDA trajectory. The bear case is more granular but persistent: per-account service fees are declining even as total accounts grow, and elevated security costs are compressing service gross margins — a headwind management has flagged as ongoing. Valuation is not stretched on the metrics available; EV/EBITDA has eased roughly half a turn over the past month to 12.2x, and the P/E at 17.5x is modest for a company with this growth profile. EPS momentum scores are strong — ranking in the 76th percentile on a 30-day basis — suggesting estimate revisions are still running in the right direction even if the year-on-year trajectory has moderated from the extraordinary levels seen in late 2025.
Insider activity warrants a mention. Several executives sold shares in late May, with the General Counsel offloading 7,500 shares at $90 on May 28 — the day of the earnings print — and the Chief Commercial Officer selling 3,142 shares at $95 the following day. Those sales sit in the context of a broader 90-day insider net of roughly $6 million in disposals, covering multiple C-suite names including the CEO and CFO, who both sold in early April. None of these are alarm-sized relative to the company, but the cluster of post-earnings selling at prices above today's level is worth registering.
Peer performance on the week was mixed, offering no clear sector tailwind. GH gained 8.6% on the week, but CRVL fell 5.6% and LH was essentially flat. The next scheduled earnings event is June 25. Whether the bull case holds through that date turns on whether management's confidence in raised guidance — and specifically, any update on the service-fee compression trend — is matched by the numbers.
See the live data behind this article on ORTEX.
Open HQY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
